Extended lifespan of bronchial epithelial cells maintains normal cellular phenotype and transcriptome integrity

Jonathan O’Loughlin¹,⁴, Robert J. Hall O¹,⁴, Sangita Bhaker¹, Michael A. Portelli¹, Amanda Henry¹, Vincent Pang², David O. Bates², Tyson V. Sharp³ and Ian Sayers¹,⁴

Affiliations: ¹Division of Respiratory Medicine, National Institute for Health Research, Nottingham Biomedical Research Centre, Biodiscovery Institute, University of Nottingham, Nottingham, UK. ²Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Biodiscovery Institute, Nottingham, UK. ³Centre of Cancer Cell and Molecular Biology, Barts Cancer Institute Queen Mary University of London, London, UK. ⁴These authors contributed equally.

Correspondence: Robert J. Hall, Division of Respiratory Medicine, National Institute for Health Research, Nottingham Biomedical Research Centre, Biodiscovery Institute, University of Nottingham, Nottingham, NG7 2RD, UK. E-mail: robert.hall@nottingham.ac.uk

ABSTRACT Genetic studies have identified several epithelial-derived genes associated with airway diseases. However, techniques used to study gene function frequently exceed the proliferative potential of primary human bronchial epithelial cells (HBECs) isolated from patients. Increased expression of the polycomb group protein BMI-1 extends the lifespan of HBECs while maintaining cell context plasticity. Herein we aimed to assess how BMI-1 expression impacted cellular functions and global mRNA expression. HBECs from six donors were transduced with lentivirus containing BMI-1 and cells were characterised, including by RNA sequencing and impedance measurement. BMI-1-expressing HBECs (B-HBECs) have a proliferative advantage and show comparable in vitro properties to low passage primary HBECs, including cell attachment/spreading and barrier formation. The B-HBEC mRNA signature was modestly different to HBECs, with only 293 genes differentially expressed (5% false discovery rate). Genes linked to epithelial mesenchymal transition and cell cycle were enriched in B-HBECs. We investigated the expression of genes implicated in asthma from genetic and expression studies and found that 97.6% of genes remained unaltered. We have shown that increased BMI-1 expression in HBECs delays lung epithelial cell senescence by promoting cell cycle progression and highlighted the flexible utility for B-HBECs as an important platform for studying airway epithelial mechanisms.
Introduction

The proximal airway epithelium is a critical defensive barrier that protects underlying tissues from inhaled pathogens and environmental particles by orchestrating innate and adaptive immune responses. In chronic airway diseases such as asthma there is growing evidence that the airway epithelium is fundamentally different in a number of aspects, including the epigenome and transcriptome [1], cell composition [2], and barrier properties [3]. Genome-wide association studies (GWASs) and RNA-sequencing studies have identified numerous genetic variants (e.g. within IL33, TSLP gene loci [4, 5]) and differentially expressed genes of relevance to the airway epithelium (CEACAM5, CPA3, INSR, MS4A2, NOXI, and SLC16A6 [6]). Many genes identified from these studies are novel and thus their contribution to airway disease have yet to be elicited and importance defined.

Culturing primary human bronchial epithelial cells (HBECs) isolated from healthy controls or asthmatic patients at the air–liquid interface (ALI) is the gold standard for studying physiologically relevant lung epithelial biology [7]. However, the short lifespan (3–4 passages) of primary airway epithelial cells when cultured in vitro, is insufficient for many in vitro techniques such as CRISPR/cas9 gene editing and single cell cloning prior to ALI. Thus, there is a need for a cell culture model with an enhanced lifespan potential, whilst retaining the plasticity and phenotype of primary epithelial cells. This is particularly important as the bronchoscopy procedure to isolate cells has significant risks to the donor.

There have been numerous different approaches to resolve primary epithelial cell senescence, including culturing cells with Rho-associated protein kinase (ROCK) inhibitors, seeded on a layer of irradiated feeder cells [8]. Whilst such methods allow normal epithelial cells to proliferate indefinitely in vitro, it is complex and time-consuming when compared to standard cell culture methods. Alternative methods have overexpressed proteins such as human telomerase reverse transcriptase (hTERT) within cells to successfully extend their proliferative potential [9]. However, hTERT-expressing cells have been shown to lose the ability to differentiate at early passage and be genetically unstable [9, 10]; two key elements required comparable to wild type cells for in vitro disease research.

B-cell-specific Moloney murine leukaemia virus integration site 1 (BMI-1) is a polycomb group protein that is critical in regulating cell senescence through suppression of the cyclin-dependent kinase inhibitor, p16INK4A [11, 12]. We have shown that cells engineered to overexpress BMI-1 retain key phenotypes of primary bronchional epithelial cell cultures up to passage 15, including the ability to differentiate at the ALI and a normal karyotype, which has been robustly replicated by others [10, 13]. However, all of these studies have lacked the fundamental understanding of the global gene expression profile that is manipulated, deregulated and controlled in the context of BMI-1 overexpression. This is essential if we are to expand and effectively utilise this important lung cell culture platform for basic and disease biology.

In this study, we have addressed the previously uncharacterised biology of this lung cell model system. We have 1) evaluated the BMI1-HBEC (B-HBEC) system in detail as a platform representative of primary human airway epithelium at both the cellular and molecular level; 2) developed an inducible BMI-1 system that can be silenced allowing a research platform directly comparable to low passage donor cells; and 3) evaluated the utility of the platform to investigate genes implicated in asthma.

Materials and methods

Primary bronchial epithelial cell culture

Normal HBECs (N-HBECs) were purchased from Lonza (Wokingham, UK) (supplementary table S1). N-HBECs were grown in BEGM (Lonza) supplemented with 13 mg·mL\(^{-1}\) bovine pituitary extract, 0.5 mg·mL\(^{-1}\) hydrocortisone, 0.5 µg·mL\(^{-1}\) human recombinant epidermal growth factor, 0.5 mg·mL\(^{-1}\) epinephrine, 10 mg·mL\(^{-1}\) transferrin, 5 mg·mL\(^{-1}\) insulin, 0.1 µg·mL\(^{-1}\) retinoic acid, 6.5 µg·mL\(^{-1}\) triiodothyronine, 30 µg·mL\(^{-1}\) gentamicin and 5 ng·mL\(^{-1}\) amphotericin as previously described [7].

Production of genetically modified HBECs

Full length human BMI-1 was amplified and cloned into a pLVX-Puro constitutive vector (Clontech) and a pCDH-CaO-MCS-IREs-RFP (SparQ) inducible vector (System Biosciences). pLVX-Puro-BMI-1, SparQ-BMI-1 and pCDH-EF1-CymR-T2A-Puro (System Biosciences) vectors were packaged into pCMV delta R8.9 and pCMV-VSV-G lentivirus envelope and packaging vectors. Passage 2 N-HBECs from six donors were transduced with pLVX-Puro-BMI-1 lentivirus solution to produce HBECs that constitutively express BMI-1 (B-HBEC), as described previously [10]. These B-HBECs were continued in culture through additional passages 3, 4, 5 and 6. To generate an inducible BMI-1 cell line, N-HBECs from five donors were transduced with SparQ-BMI-1 lentivirus solution and pCDH-EF1-CymR-T2A-Puro lentivirus solution (1:3 ratio). Additional details are described in the supplementary material.
**MTT assay**

A total of 2.5x10^3 cells were seeded onto a 96-well plate in 200 µL of BEGM. Cells were incubated for 72 or 96 h. Medium was replaced with 200 µL 0.5 mg·mL⁻¹ 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) dissolved in BEGM. Cells were incubated with MTT at 37°C for 4 h. MTT solution was replaced with 200 µL isopropanol and incubated for 10 min. The absorbance of the solution was measured at 570 nm (subtracting the 690 nm background) using a Flexstation 3 microplate reader (Molecular Devices, Wokingham, UK).

**DAPI staining**

Cells suspended in BEGM were transferred into a Via-1 Cassette, lined with acridine orange and 4',6-diamidino-2-phenylindole (DAPI) and analysed on a Nucleocounter NC-3000 (Chemometec, Allerod, Denmark).

**Electric cell-substrate impedance sensing**

The 8W10E arrays (IBIDI, Munich, Germany) were treated with 200 µL 10 mM L-cysteine dissolved in sterile water for 15 min at room temperature. Wells were washed 3x with 300 µL sterile water. Then, 200 µL PureCol Type 1 bovine collagen solution (Advanced Biomatrix, San Diego, CA, USA) diluted 1 in 100 in sterile water, was added to wells and incubated at 37°C overnight. Wells were washed 3x with BEGM. Then, 400 µL BEGM was added to each well and the array was stabilised in the electric cell-substrate impedance sensing (ECIS Zθ instrument (Applied Biophysics, Troy, NY, USA). Medium was replaced with 7.5x10^4 cells in BEGM. The array was run at multiple frequencies (including the specific frequencies of 400 Hz and 32 kHz) for 72 h continuously on the ECIS Zθ instrument, as described previously [14].

**Two-step cell cycle assay**

A total of 4x10^5 cells were centrifuged at 400xg for 5 min. Pellets were washed with PBS then resuspended in 100 µL lysis buffer (Chemometec) containing 10 µg·mL⁻¹ DAPI (Chemometec) and incubated at 37°C for 5 min. Then, 100 µL stabilisation buffer (Chemometec) was added to the solution and 30 µL of sample was transferred into an NC-Slide A2 (Chemometec). A two-step cell cycle assay was run on a Nucleocounter NC-3000 (Chemometec). Data were exported as an FCS file and analysed using FlowJo software. The cell cycle distribution for 10 000 cells was automatically quantified using the cell cycle modelling algorithm as described [15].

**RNA extraction and isolation**

Cells were grown in T75 flasks until 80% confluent. RNA was isolated using an RNeasy Mini Kit (QIAGEN, Manchester, UK) following the manufacturer’s protocol. RNA integrity number was assessed using the 2100 Bioanalyser (Agilent, Didcot, UK).

**RNA sequencing**

Library preparation is described in the supplementary material. Paired-end (75 bp) sequencing was performed using a HiSeq4000 platform, HiSeq 3000/4000 PE Cluster kit and 150 cycle SBS kit (Illumina, Cambridge, UK), generating a raw read count of ~30 million reads per sample.

**Analysis of RNA sequencing**

Alignment of RNA-sequencing reads to genome build GRCh37 was carried out using TopHat package [16]. Analysis of RNA-sequencing files was performed using the Cufflinks package [16] as performed previously [17]. Principal-component analysis (PCA) was completed using the R package pcomp using FPKM values generated by Cuffnorm and PCA plots were produced using ggplot2. Additional details are described in the supplementary material.

**Lookup of asthma-related genes**

A lookup of asthma-related genes was performed in the generated RNA-sequencing datasets. Asthma-related genes were identified from the most recent and largest asthma GWAS [5] and from meta-analyses of gene expression in bronchial epithelial brush samples from asthma patients and controls [6].

**Statistical analysis**

For cell-based outcomes, a paired t-test was used to determine differences between N-HBECs and B-HBECs. To determine whether BMI-1 expression altered cell cycle phase frequency, a two-way ANOVA with Sidak’s multiple comparisons test was performed. p<0.05 was considered significant.

https://doi.org/10.1183/23120541.00254-2020
Results

BMI-1 does not change the viability of HBECs
To determine the effects of BMI-1 upregulation on cell viability, an MTT assay was performed. The cell viability of passage 3 (P3) N-HBECs were compared to passage 6 (P6) B-HBECs from six donors (supplementary table S1). At both 72 and 96 h, there was a nonsignificant increase in cell viability in five of six B-HBEC donors (figure 1a and b). Staining with DAPI to assess cell viability also showed no difference between B-HBECs and N-HBECs populations (figure 1c).

BMI-1 expression alters cell cycle distribution of HBECs
We observed a significant decrease of 12% in the frequency of B-HBECs within the G1/G0 phase (p<0.001) and an increase of 9% in G2/M phase cells (p<0.01) when compared to N-HBECs (figure 1d and supplementary figure S1).

BMI-1 does not impact cell spreading or tight junction formation in HBECs
To assess how BMI-1 overexpression impacted cell adherence, spreading or tight junction formation we performed ECIS. In all comparisons of N-HBEC versus B-HBEC no difference was observed for capacitance (cell spreading/adherence) or resistance (tight junction formation), highlighting that B-HBECs are not different from N-HBECs in these properties (figure 2).

Constitutive overexpression of BMI1 in N-HBECs produces a transcriptional response
To determine how BMI-1 expression affected HBECs at the transcriptome level, RNA sequencing was performed using RNA isolated from early passage (P2) N-HBECs and P5 B-HBECs (figure 3a). PCA of N-HBECs and B-HBECs identified significant overlap in the sample datasets with no obvious outliers (supplementary figure S2). We first confirmed that all six HBECs donors transduced with pLVX-BMI-1 had significant upregulation of BMI-1 transcripts in comparison to N-HBECs (figure 3b; p<0.0001). Of

FIGURE 1 Phenotypic properties of BMI-1-expressing human bronchial epithelial cells [B-HBECs] and normal human bronchial epithelial cells [N-HBECs]. Basic cell phenotypes of passage 3 N-HBECs and passage 6 B-HBECs derived from the same matched donors. a and b) An MTT [3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide] assay was performed to assess cell viability; cells were incubated for 72 h [a] and 96 h [b] before the addition of MTT. c) Cell viability determined through DAPI staining and counted on a Chemometec Nucleocounter NC-3000. d) The cell cycle phase distribution in N-HBECs and B-HBECs determined through a two-step cell cycle assay with cell cycle phase frequency, calculated using the Watson pragmatic algorithm. Values represent the median and 95% confidence interval (n=6). A paired t-test [a–c], two-way ANOVA and Sidak’s multiple comparison test [d] were used to determine statistical significance. **: p<0.01; ***: p<0.001.
the 19,190 transcripts evaluated, 293 genes (1.5%) were differentially expressed at 5% false discovery rate (FDR). There were 161 genes that were upregulated and 132 were downregulated in B-HBECs compared to N-HBECs (figure 3c). The top 10 upregulated genes based on magnitude of effect and p-value were; GUSBP2, HAS2, THY1, DENND2A, TOX2, CSF3, CPNE7, CSF3, ATP1A3, BCL2A1 and those downregulated were; COX7A1, HEATR6, SPINK7, ATPIA3, PROSP, MUC15, SPRR3, CALB1, SBSN, KRT13 (table 1 and figure 3c). We observed multiple changes to extracellular matrix proteins, including increases in collagen genes (COL4A1, COL4A2, COL22A1) and decreases in cytokeratin genes (KRT4, KRT10, KRT13, KRT16, KRT23) in B-HBECs (supplementary table S2 for complete list). A heat map was generated using genes with a five-fold or greater change in expression, demonstrating that there was heterogeneity at the donor level. However, the expression profiles of N-HBECs and B-HBECs are visibly distinct for these highest differentially expressed genes (figure 3d).

Gene set enrichment analysis shows that genes involved in cell cycle regulation are altered in B-HBECs
To provide an insight into how BMI-1 expression affected the biological processes of bronchial epithelial cells we used gene set enrichment analysis. A total of 143 pathways were enriched in B-HBECs.
FIGURE 3 RNA sequencing analysis of BMI-1-expressing human bronchial epithelial cells (B-HBECs) versus normal human bronchial epithelial cells (N-HBECs). a) Schematic showing the RNA-sequencing pipeline. Scythe/Sickle trimmed Fastq files (.fastq) were aligned to the GRCh37 human genome assembly to produce BAM files (.bam) with an average of \( \sim 40 \) million mapped reads using the TopHat software package. Cufflinks and Cuffmerge were used for transcript assembly and Cuffnorm and Cuffdiff were used for normalised and differential gene expression, respectively. b) Total BMI-1 expression (FPKM) in P2 N-HBECs and P5 B-HBECs. Statistical analysis was carried out using a paired t-test (***: p<0.0001). c) 293 genes were differentially expressed between B-HBECs and N-HBECs with 132 downregulated and 161 upregulated (5% false discovery rate). Coloured dots represent differentially expressed genes (q<0.05) and labelled genes are the top 10 differentially expressed genes ranked firstly on q-value then on fold change. d) Genes that showed a >5-fold change in expression (q=0.006). Red represents over expressed, and blue attenuated genes.
(upregulated by BMI-1) whilst 20 pathways were enriched in N-HBECS (downregulated by BMI-1) at 5% FDR (supplementary table S3). The most upregulated pathways in B-HBECs consisted of genes involved in epidermal growth factor receptor (EGFR) signalling (normalised enrichment score (NES) 2.23), cell-cycle regulated genes (NES 2.06 and 2.04) and epithelial mesenchymal transition (EMT) (NES 2.02) (table 2). The top downregulated pathway in B-HBECs involved genes in intestinal cells in response to co-culture with probiotic bacteria (NES −2.11) and mucociliary differentiation (NES −2.01). These gene and pathway data indicate that BMI-1 expression induces changes in the expression profile of several pathways and 2) provide an expression map for researchers interested in using this platform for specific pathway-related questions.

**BMI-1 expression in an inducible model is not reversible and shows heterogeneity**

In addition to the constitutive B-HBEC cell line, we developed a second-generation cell system with inducible BMI-1-expression HBECS (IB-HBECs) controlled through a cumate switch. We confirmed that IB-HBECs cultured in the presence of cumate have significantly upregulated BMI-1 transcripts (\(^p<0.05\)). However, withdrawal of cumate had either no effect or a modest decrease on BMI-1 expression levels (figure 4a). Overall, 104 genes out of 16 384 assayed (0.6%), were differentially expressed between N-HBECs and IB-HBECs cultured in the presence of cumate (supplementary table S4). This is markedly fewer than we observed in the constitutive B-HBEC system (figure 4b). Of these, 74 genes were upregulated, whilst 30 genes were downregulated in comparison to N-HBECs. The top 10 upregulated genes included: NES, SI00A7, TSPAN18, NTRK1, BMI1/COMMD3, ANPEP, B4GALNT1, COL8A2, CA14 and HEPHL1 and downregulated genes included: CLCA4, AC005702.1/AC005702.4, KRT13, KRT4, MSMB, NDN, ATP12A, CRNN, ALDH3A1 and METTL7A ranked as previously (figure 4b). It is evident that

| Gene   | Direction/fold change | Description                                                                 |
|--------|-----------------------|-----------------------------------------------------------------------------|
| GUSBP2 | +52                   | Pseudogene.                                                                  |
| HAS2   | +42                   | Hyaluronan synthase 2. Hyaluronan or hyaluronic acid is a constituent of the extracellular matrix. It serves a variety of functions, including space filling, lubrication of joints and provision of a matrix through which cells can migrate. |
| THY1   | +16                   | Thy-1 cell surface antigen. The encoded protein is involved in cell adhesion and cell communication in numerous cell types, but particularly in cells of the immune and nervous systems. |
| DENND2A| +15                   | DENN domain containing 2A. Guanine nucleotide exchange factor, which may activate RAB9A and RAB9B. Promotes the exchange of GDP to GTP, converting inactive GDP-bound Rab proteins into their active GTP-bound form. |
| TOX2   | +12                   | TOX high mobility group box family member 2. Gene Ontology annotations related to this gene include chromatin binding and RNA polymerase II transcription factor binding. |
| CSF3   | +10                   | Colony stimulating factor 3. The protein encoded by this gene is a cytokine that controls the production, differentiation and function of granulocytes. |
| CPNE7  | +9                    | Copine 7. Calcium-dependent membrane-binding proteins.                        |
| ATP1A3 | +9                    | ATPase Na+/K+ transporting subunit α3. The protein encoded by this gene belongs to the family of p-type cation transport ATPases, and to the subfamily of Na+/K+ -ATPases. |
| BCL2A1 | +8                    | BCL2 Related protein A1. This gene encodes a member of the BCL-2 protein family. The proteins of this family form hetero- or homodimers and act as anti- and proapoptotic regulators that are involved in a wide variety of cellular activities such as embryonic development, homeostasis and tumourigenesis. |
| KIAA1644| +7                   | Unknown function.                                                          |
| COX7A1 | -Infinite             | Cytochrome C oxidase subunit 7A1. Cytochrome c oxidase, the terminal component of the mitochondrial respiratory chain, catalyses the electron transfer from reduced cytochrome c to oxygen. |
| HEATR6 | −70                   | Diseases associated with HEATR6 include breast cancer.                      |
| SPINK7 | −44                   | Serine peptidase inhibitor, Kazal type 7. Probable serine protease inhibitor. |
| ATP12A | −43                   | ATPase H+/K+ transporting nongastric α2 subunit. The protein encoded by this gene belongs to the family of P-type cation transport ATPases. |
| PROSP  | −32                   | Pseudogene.                                                                 |
| MUC15  | −29                   | Mucin 15. Cell surface Associated. May play a role in the cell adhesion to the extracellular matrix. |
| SPRR3  | −14                   | Small proline rich protein 3. Among its related pathways are keratinisation and developmental matrix. |
| CALB1  | −14                   | Calbindin 1. This protein is thought to buffer entry of calcium upon stimulation of glutamate receptors. |
| SBSN   | −13                   | Suprabasin. Diseases associated with SBSN include adenoid cystic carcinoma. |
| KRT13  | −12                   | Keratin 13. The keratins are intermediate filament proteins responsible for the structural integrity of epithelial cells and are subdivided into cytokeratins and hair keratins. |

N-HBEC: normal human bronchial epithelial cell; B-HBEC: BMI-1-expressing human bronchial epithelial cells.
N-HBECs have a distinct expression profile compared to IB-HBECs and that there is no distinct difference between IB-HBECs that have BMI-1 expression switched on (+cumate) and IB-HBECs that have BMI-1 silenced (−cumate) (figure 4c and supplementary table S5). Finally, we compared the expression profile of constitutive and inducible B-HBECs, of the total 293 genes that were differentially expressed between B-HBECs and N-HBECs, just 20 of those genes were also differentially expressed between IB-HBECs and N-HBECs (figure 4d).

**BMI-1 constitutive expressing cell platform has a physiologically valid utility for asthma research**

To begin to address the utility of the BMI-1 constitutive cell lines for asthma research we investigated the expression profile of genes implicated in asthma in the most recent and largest GWAS [5] and in a

### TABLE 2 Gene set enrichment analysis was carried out to identify differentially regulated pathways between P2 N-HBECs and P5 B-HBECs

| NAME                                                                 | Direction | SIZE | ES   | NES  | FDR q-value | Leading edge |
|----------------------------------------------------------------------|-----------|------|------|------|-------------|--------------|
| KOBAYASHI EGFR SIGNALING_24HR_DN                                     | Upregulated | 244  | 0.74 | 2.23 | 0           | tags: 74%, list: 16%, signal: 88% |
| ROSTY CERVICAL CANCER PROLIFERATION CLUSTER                         | Upregulated | 137  | 0.74 | 2.13 | 0           | tags: 84%, list: 18%, signal: 102% |
| SOTIRIOU BREAST CANCER GRADE 1_VS_ 3 UP                              | Upregulated | 146  | 0.74 | 2.13 | 0           | tags: 85%, list: 18%, signal: 103% |
| MANALO HYPOXIA DN                                                    | Upregulated | 282  | 0.69 | 2.11 | 0           | tags: 65%, list: 15%, signal: 75% |
| DUTERTRE ESTRADIOL_RESPONSE_24HR UP                                  | Upregulated | 316  | 0.68 | 2.10 | 0           | tags: 68%, list: 15%, signal: 80% |
| BLUM RESPONSE TO SALIRASIB_DN                                       | Upregulated | 340  | 0.66 | 2.06 | 0           | tags: 70%, list: 18%, signal: 85% |
| ZHOU CELL CYCLE GENES IN IR RESPONSE 6HR                            | Upregulated | 82   | 0.77 | 2.06 | 0           | tags: 78%, list: 14%, signal: 91% |
| ZHOU CELL CYCLE GENES IN IR RESPONSE 24HR                            | Upregulated | 123  | 0.73 | 2.04 | 0           | tags: 77%, list: 17%, signal: 93% |
| SARRIO EPITHELIAL MESENCHYMAL TRANSITION UP                          | Upregulated | 173  | 0.69 | 2.02 | 0           | tags: 73%, list: 18%, signal: 88% |
| FOURNIER ACINAR_DEVELOPMENT_LATE_2                                   | Upregulated | 270  | 0.66 | 2.01 | 0           | tags: 64%, list: 16%, signal: 76% |
| ZHOU CELL CYCLE GENES IN IR RESPONSE 6HR                             | Upregulated | 213  | −0.69 | −2.11 | 0           | tags: 82%, list: 21%, signal: 103% |
| BOSCO EPITHELIAL DIFFERENTIATION MODULE                              | Downregulated | 69   | −0.75 | −2.01 | 2.57×10⁻⁴ | tags: 74%, list: 18%, signal: 90% |
| KEGG RIBOSOME                                                        | Downregulated | 88   | −0.73 | −2.03 | 3.85×10⁻⁴ | tags: 83%, list: 23%, signal: 114% |
| REACTOME SRP_DEPENDENT_COTRANSLATIONAL PROTEIN TARGETING TO MEMBRANE | Downregulated | 126  | −0.68 | −1.98 | 4.69×10⁻⁴ | tags: 83%, list: 23%, signal: 107% |
| REACTOME Peptide_chain_elongation                                     | Downregulated | 102  | −0.72 | −1.98 | 5.86×10⁻⁴ | tags: 87%, list: 23%, signal: 113% |
| RICKMAN HEAD_AND_NECK_CANCER_E                                       | Downregulated | 87   | −0.71 | −1.94 | 0.00184    | tags: 71%, list: 17%, signal: 85% |
| REACTOME 3_UTR_MEDIATED_TRANSLATIONAL_REGULATION                      | Downregulated | 123  | −0.66 | −1.93 | 0.00203    | tags: 71%, list: 19%, signal: 87% |
| REACTOME TRANSLATION                                                 | Downregulated | 165  | −0.63 | −1.88 | 0.00587    | tags: 66%, list: 19%, signal: 82% |
| REACTOME NONSENSE MEDIATED DECAY ENHANCED BY THE_EXON_JUNCTION_COMPLEX | Downregulated | 123  | −0.64 | −1.87 | 0.00609    | tags: 80%, list: 23%, signal: 103% |
| HOLLERN EMT_BREAST_TUMOR_DN                                          | Downregulated | 95   | −0.65 | −1.82 | 0.01532    | tags: 51%, list: 12%, signal: 57% |

143 pathways were significantly ($q<0.05$) enriched in B-HBECs and 20 were enriched in the N-HBECs (top 10 shown ranked on q-value and then ES). Size indicates the number of genes in the gene set after filtering out those not in the expression dataset.N-HBEC: normal human bronchial epithelial cell; B-HBEC: BMI-1-expressing human bronchial epithelial cells; ES: enrichment score for the gene set, which is the degree that the gene set is over-represented at the top or bottom of the ranked list of genes in the expression dataset; NES: normalised enrichment score; FDR q-value: false discovery rate adjusted p-value, which is the estimated probability that the NES represents a false positive; leading edge subset: subset of members that contribute the most to the ES; tags: percentage of genes contributing to the ES.
FIGURE 4 RNA sequencing analysis of inducible BMI-1-expressing human bronchial epithelial cells (IB-HBECs) cultured with and without cumate. a) Total BMI-1 expression (FPKM) in P2 normal human bronchial epithelial cells (N-HBECs), P5 inducible HBECs (IB-HBECs) in the presence of cumate and P6 IB-HBECs with cumate washed out. Statistical analysis carried out with a Friedman test with Dunn’s multiple comparisons test (*: p<0.05). b) 104 genes are differentially expressed between BMI-1-expressing and endogenous cells with 74 genes upregulated and 30 genes downregulated (5% false discovery rate). Coloured dots reached q<0.05 and labelled genes are the top 10 differentially expressed genes ranked firstly on q-value then fold change. c) Genes that showed a >5-fold change in expression (q=0.006) between IB-HBECs and N-HBECs, including the expression levels after cumate withdrawal. Red represents high expression and blue low. d) Venn diagram showing the proportion of genes that are differentially expressed in both the constitutive and inducible B-HBEC systems.
Previous studies that have manipulated BMI-1 expression have shown widespread changes to gene cell behaviour for mechanistic studies. When cultured at ALI [10], indicating that a robust epithelial barrier model can be achieved. However, we have previously shown that differentiated B-HBECs develop a resistive barrier comparable to that cells are cultured in an undifferentiated state and therefore not representative of (5% FDR). Although a significant number, a comparison of gene expression between 6 pathway in B-HBECs consisted of genes involved in EGFR signalling, a pathway that has previously been implicated in disease mechanisms and where obtaining cell samples from control subjects and asthma patients comes with associated risk.

BMI-1 is implicated in a number of different cancers largely due to its role in stem-cell renewal but also its regulation of proliferation [23–25]. Collectively, when we compared the cell viability of N-HBECs and B-HBECs, no statistically significant difference was observed, although individually 5/6 B-HBEC donors showed an increase. We also observed no difference in cell viability between N-HBECs and B-HBECs, although cell viability was high (>85%) in each cell line.

The transcriptional repressor, BMI-1, is part of the polycomb repressive complex-1 and one of the target genes of this complex is thought to be CDKN2A (p16INK4A) [22]. We have confirmed downregulation of p16 protein previously [10] and now show that B-HBECs progress through the G1/S checkpoint more readily compared to N-HBECs. Downregulation of CDKN2A was observed in our differential gene expression analysis (mean FPKM 32, (range 21–46) in N-HBEC versus mean FPKM 20, (range 9–26) in B-HBEC); however, this did not reach statistical significance.

BMI-1 is implicated in a number of different cancers largely due to its role in stem-cell renewal but also its regulation of proliferation [23–25]. Collectively, when we compared the cell viability of N-HBECs and B-HBECs, no statistically significant difference was observed, although individually 5/6 B-HBEC donors showed an increase. We also observed no difference in cell viability between N-HBECs and B-HBECs, although cell viability was high (>85%) in each cell line.

ECIS has previously been shown to be a sensitive and noninvasive technique for measuring multiple in vitro properties of bronchial epithelial cells [26]. We showed that N-HBECs and B-HBECs attach and spread in a highly similar manner. Previous studies have found that upregulation of BMI-1 results in the downregulation of E-cadherin and the upregulation of EMT markers [27–29]. One limitation of ECIS is that cells are cultured in an undifferentiated state and therefore not representative of in vivo conditions. However, we have previously shown that differentiated B-HBECs develop a resistive barrier comparable to N-HBECs when cultured at ALI [10], indicating that a robust epithelial barrier model can be achieved. This is particularly of relevance to asthma, as bronchial epithelial cells isolated from asthma patients have defective barrier properties [3] and the BMI-1 platform may be useful to extend the lifespan of patient cells for mechanistic studies.

Previous studies that have manipulated BMI-1 expression have shown widespread changes to gene expression as a consequence [30]. BMI-1−/− in neural progenitor cells resulted in over 500 genes being upregulated alone [31]. We identified 293 genes to be differentially expressed due to BMI-1 upregulation (5% FDR). Although a significant number, a comparison of gene expression between in vivo airway epithelia and differentiated airway epithelial cells cultured at the ALI, found 453 genes that were differentially expressed with a more stringent <1% FDR [32]. Whilst BMI-1 expression did not result in widespread changes in expression to key epithelial cell markers, significantly, BMI-1 downregulated transcripts that are associated with epithelial differentiation pathways (KRT7, KRT13, SPINK5, CEACAMS/6, SPRR1A and SPRR1B). KRT4 and KRT13 are markers of a newly identified transitional cell identified in the mouse airway [33], a finding which requires further investigation.

We observed many pathways (>150) that were significantly altered by BMI-1. The most upregulated pathway in B-HBECs consisted of genes involved in EGFR signalling, a pathway that has previously been...
associated with chronic airway diseases such as asthma [34, 35]. The regulatory role that BMI-1 has in the cell cycle has been well characterised and it was therefore anticipated that two of the most enriched pathways in B-HBECs related to cell cycle genes [36, 37], BMI-1 expression also increased expression of genes associated with cell proliferation and EMT; these findings are supported by the literature linking BMI-1 to multiple different cancers [24, 25, 38, 39]. This characterisation provides information for researchers using this platform.

The use of BMI-1 to expand the replicative lifespan of HBECs will potentially allow us to capture the phenotype of HBECs derived from bronchial brushes for a range of respiratory disease patients including asthma. Our data from these analyses indicate that the upregulation of BMI-1 does not reduce inter-donor variability. Furthermore, BMI-1 has previously been utilised to delay cell senescence in cystic fibrosis cells, whilst retaining their disease phenotype [13]. The extended lifespan of these cells gives researchers more scope for experiments such as CRISPR/cas9 gene editing and single cell cloning prior to ALI expansion. This is challenging in primary airway cells as ALI is required to be performed on early passage cells, limiting the capacity of the cells to undergo manipulation prior to ALI.

GWAS and RNA-sequencing studies of asthma have identified multiple candidate genes linked to disease and we found that the majority of these (97.6%) were not influenced by BMI-1 overexpression, supporting the use of this platform. Seven of these genes were significantly differentially regulated by BMI-1 over expression (downregulated: SERPINB7, CYP2J2, UPK1B, SNTB1 and CEACAMS; upregulated: ITGB6 and EFNBR2).

To avoid the effects of prolonged BMI-1 expression we also produced an inducible BMI-1 HBEC platform, regulated by a cumate switch system. We observed significant upregulation of BMI-1 in IB-HBECs cultured in cumate-supplemented medium, although more heterogeneous than the constitutive system. When cumate was withdrawn from the culture medium, BMI-1 expression did not return to basal levels observed in N-HBECs, although some donors did show a reduction. This finding, further supported by the limited concordance in B-HBEC and IB-HBEC transcriptomes, suggests that the inducible platform has limited utility.

The major limitation of this study is that we did not overexpress BMI-1 in cells isolated from asthma patients to compare to healthy controls, however this was beyond the primary aim of the present study. We have previously shown that BMI-1 HBECs maintain the ability to differentiate and form an epithelial barrier at ALI; however, it is as yet unclear as to whether BMI-1-overexpressing cells derived from asthma patients would exhibit an altered phenotype at the ALI [10]. It is also important to note that several changes observed in the B-HBECs are relevant to asthma phenotypes including changes to matrix proteins, mucociliary differentiation, EGFR signalling and EMT [35, 40]. Therefore, additional caution and characterisation is required prior to B-HBECs being confirmed as a suitable cell model for asthma mechanisms.

In conclusion, this study highlights the utility of the constitutive BMI-1 platform for capturing and studying the phenotype of airway epithelial cells, whilst retaining interdonor variability. This provides a platform to investigate disease mechanisms over prolonged periods and reducing reliance on bronchial brushes and biopsies, procedures that are invasive and present a risk for patients with airway disease. Finally, the extended lifespan of cells will provide a platform for more challenging mechanistic studies that may require frequent cell passaging (e.g. CRISPR/Cas9 gene and variant editing).

Author Contributions: I. Sayers conceived and designed the study. T.V. Sharp contributed to the design of the study. J. O’Loughlin and R. Hall designed and completed experiments, and analysed data. S. Bhaker, M.A. Portelli and A. Henry performed experiments and analysed data. V. Pang and D.O. Bates facilitated the design of ECIS experiments. I. Sayers, J. O’Loughlin and R. Hall wrote the paper with contributions from all authors.

Conflict of interest: J. O’Loughlin has nothing to disclose. R. Hall has nothing to disclose. S. Bhaker has nothing to disclose. M.A. Portelli has nothing to disclose. A. Henry has nothing to disclose. V. Pang has nothing to disclose. D.O. Bates has nothing to disclose. T.V. Sharp has nothing to disclose. I. Sayers reports grants from Asthma UK, the Hermes Fellowship and the British Lung Foundation during the conduct of the study and grants from GSK and Boehringer Ingelheim outside the submitted work.

Support statement: This study was supported by Asthma UK (grants 10/006 and 11/031), a Hermes Fellowship (University of Nottingham, 2016–2017), the British Lung Foundation (grant PPRG15–5) and the British Heart Foundation (grant PG/13/85/30536). Funding information for this article has been deposited with the Crossref Funder Registry.

References

1 Nicodemus-Johnson J, Myers RA, Sakabe NJ, et al. DNA methylation in lung cells is associated with asthma endotypes and genetic risk. *JCI Insight* 2016; 1: e90151-e.
García-Escudero V, García-Gómez A, Gargini R, Liu X, Ory V, Chapman S, Heijink IH, van Oosterhout A, Kapus A. Epidermal growth factor receptor signalling contributes to house dust mite-induced epithelial barrier dysfunction. *Am J Physiol Lung Cell Mol Physiol* 2010; 300: L258–L267.

Wegener J, Keese CR, Giaever I. Electric cell-substrate impedance sensing (ECIS) as a noninvasive means to monitor the kinetics of cell spreading to artificial surfaces. *Exp Cell Res* 2000; 259: 158–166.

Watson JV, Chambers SH, Smith MF. A pragmatic approach to the analysis of DNA histograms with a definable G1 peak. *Cytometry* 1987; 8: 1–8.

Trappe C, Roberts A, Goff L, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. *Nat Protoc* 2012; 7: 562–578.

Kheirallah AK, de Moor CH, Faiz A, et al. Lung function associated gene integrator complex subunit 12 regulates protein synthesis pathways. *BMC Genomics* 2017; 18: 248.

Zeitlin PL, Lu L, Rhim J, et al. A cystic fibrosis bronchial epithelial cell line: immortalization by adeno-12-SV40 infection. *Am J Respir Cell Mol Biol* 1994; 4: 313–319.

Coxens AL, Yezzi MJ, Kunzelmann K, et al. CFTF expression and chloride secretion in polarized immortal human bronchial epithelial cells. *Am J Respir Cell Mol Biol* 1994; 10: 38–47.

Willey JC, Broussaud A, Sleemi A, et al. Immortalization of normal human bronchial epithelial cells by human papillomaviruses 16 or 18. *Cancer Res* 1991; 51: 5370–5377.

Piao CQ, Liu L, Zhao YL, et al. Immortalization of human small airway epithelial cells by ectopic expression of telomerase. *Carcinogenesis* 2005; 26: 725–731.

Rayes HH, Wang MB, Srivatsan ES. Cellular senescence and tumor suppressor gene p16. *Int J Cancer* 2012; 130: 1715–1725.

Srinivasan M, Bharali DJ, Sudha T, et al. Downregulation of Bmi1 in breast cancer stem cells suppresses tumor growth and proliferation. *Oncotarget* 2017; 8: 38731–38742.

Wu C, Zheng X, Li X, et al. Reduction of gastric cancer proliferation and invasion by miR-15a mediated suppression of Bmi-1 translation. *Oncotarget* 2016; 7: 14522–14536.

Zhu S, Zhao D, Yan L, et al. BM1 regulates androgen receptor in prostate cancer independently of the polycomb repressive complex 1. *Nat Commun* 2018; 9: 500.

Heijink JH, Brandenburg SM, Noordhoek JA, et al. Characterisation of cell adhesion in airway epithelial cell types using electric cell-substrate impedance sensing. *Eur Respir J* 2010; 35: 894–903.

Song LB, Li J, Liao WT, et al. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. *J Clin Invest* 2009; 119: 3626–3636.

Paranipe AN, Balaji SA, Mandal T, et al. Bmi1 regulates self-renewal and epithelial to mesenchymal transition in breast cancer cells through Nanog. *BMC Cancer* 2014; 14: 785.

Pong P, Kaneuchi M, Watari H, et al. MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1. *Mol Cancer* 2011; 10: 99.

Ganapathi M, Boles NC, Charniga C, et al. Effect of Bmi1 over-expression on gene expression in adult and embryonic murine neural stem cells. *Sci Rep* 2018; 8: 7464.

Gargiulo G, Cesaroni M, Serresi M, et al. In vivo RNAi screen for Bmi1 targets identifies TGF-beta/BMP-ER stress pathways as key regulators of neural- and malignant glioma-stem cell homeostasis. *Cancer Cell* 2013; 23: 660–676.

Pezzulo AA, Starner TD, Scheetz TE, et al. The air-liquid interface and use of primary cell cultures are important in recapitulate the transcriptional profile of in vivo airway epithelia. *Am J Physiol Lung Cell Mol Physiol* 2011; 300: L258–L31.

Montoro DT, Haber AL, Biton M, et al. A revised airway epithelial hierarchy includes CFTF-expressing ionocytes. *Nature* 2018; 560: 319–324.

Puddicombe SM, Polosa R, Richter A, et al. Involvement of the epidermal growth factor receptor in epithelial repair in asthma. *FASEB J* 2000; 14: 1362–1374.

Heijink JH, van Oosterhout A, Kapus A. Epidermal growth factor receptor signalling contributes to house dust mite-induced epithelial barrier dysfunction. *Eur Respir J* 2010; 35: 1016–1026.
36 Lee K, Adhikary G, Balasubramanian S, et al. Expression of Bmi-1 in epidermis enhances cell survival by altering cell cycle regulatory protein expression and inhibiting apoptosis. J Invest Dermatol 2008; 128: 9–17.
37 Park IK, Qian D, Kiel M, et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 2003; 423: 302–305.
38 Yuan W, Yuan Y, Zhang T, et al. Role of Bmi-1 in regulation of ionizing irradiation-induced epithelial-mesenchymal transition and migration of breast cancer cells. PLoS One 2015: 10: e0118799.
39 Yong KJ, Basseres DS, Welner RS, et al. Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBPalpha expression. Sci Transl Med 2016; 8: 350ra104.
40 Bosco A, Ehteshami S, Stern DA, et al. Decreased activation of inflammatory networks during acute asthma exacerbations is associated with chronic airflow obstruction. Mucosal Immunol 2010; 3: 399–409.